Tag - BVXV

Developments

BiondVax universal flu vaccine fails Phase 3 trial

A Phase 3 clinical trial of BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal flu vaccine did not demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu...

October 23, 2020

Developments

NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints

A Phase 2 trial supported by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) concluded that BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal influenza vaccine candidate achieved safety and...

June 10, 2020

Developments

BiondVax begins NIH-sponsored universal flu vaccine trial

BiondVax Pharmaceuticals (NASDAQ:BVXV) enrolled the first participant in a U.S. Phase 2 clinical trial of its universal flu vaccine candidate, M-001. The trial is sponsored by the U.S. National Institute of Allergy and...

April 11, 2018

Feature

BiondVax to start pivotal universal flu vaccine trial next year

By Len Zehr BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) expects to be Phase 3 ready in 2018 to begin pivotal testing in Europe of a universal flu vaccine with the potential to provide multi-season and multi-strain...

September 12, 2017

Tag - BVXV

BiondVax universal flu vaccine fails Phase 3 trial

NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints

BiondVax begins NIH-sponsored universal flu vaccine trial

BiondVax to start pivotal universal flu vaccine trial next year

General

More